Payment overview · 2025
General Payments
$32.08
2 reported records · 2 companies
Healthcare provider profile · identity verified
Sarah Bashiruddin, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · WESTFIELD, MA · NPI 1396192738
Verified facts
What the public records show
CMS Open Payments records show Sarah Bashiruddin, M.D. received $32.08 in general payments during 2025 across 2 reported records.
Lilly USA, LLC accounted for 57.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 3 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Mounjaro.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 94 claims for Eliquis by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Trulicity by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $18.35 | 57.2% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $13.73 | 42.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $32.08 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $18.35 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $18.35 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C. | $13.73 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 94 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 43 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
94 | 23 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
43 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 481 | 124 |
| Levothyroxine Sodium | Levothyroxine Sodium | 346 | 77 |
| Amlodipine Besylate | Amlodipine Besylate | 315 | 89 |
| Omeprazole | Omeprazole | 286 | 73 |
| Simvastatin | Simvastatin | 274 | 67 |
| Losartan Potassium | Losartan Potassium | 260 | 67 |
| Lisinopril | Lisinopril | 242 | 64 |
| Gabapentin | Gabapentin | 186 | 54 |
| Metoprolol Succinate | Metoprolol Succinate | 164 | 43 |
| Metformin Hcl | Metformin Hcl | 153 | 41 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 152 | 50 |
| Oxycodone Hcl | Oxycodone Hcl | 135 | 20 |
| Alprazolam | Alprazolam | 132 | 23 |
| Metoprolol Tartrate | Metoprolol Tartrate | 132 | 31 |
| Sertraline Hcl | Sertraline Hcl | 121 | 34 |
| Ozempic | Semaglutide | 119 | 19 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 114 | 15 |
| Tamsulosin Hcl | Tamsulosin Hcl | 111 | 25 |
| Furosemide | Furosemide | 110 | 29 |
| Fluticasone Propionate | Fluticasone Propionate | 96 | 27 |
| Eliquis | Apixaban | 94 | 23 |
| Hydrochlorothiazide | Hydrochlorothiazide | 91 | 25 |
| Tramadol Hcl | Tramadol Hcl | 90 | 23 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 86 | 24 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 85 | 25 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 84 | 22 |
| Glipizide Er | Glipizide | 84 | 17 |
| Trazodone Hcl | Trazodone Hcl | 82 | 24 |
| Pantoprazole Sodium | Pantoprazole Sodium | 77 | 22 |
| Famotidine | Famotidine | 75 | 16 |
| Zolpidem Tartrate | Zolpidem Tartrate | 74 | 17 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 69 | 13 |
| Buspirone Hcl | Buspirone Hcl | 67 | 13 |
| Montelukast Sodium | Montelukast Sodium | 66 | 20 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 65 | 15 |
| Bupropion Xl | Bupropion Hcl | 63 | 15 |
| Lorazepam | Lorazepam | 63 | 24 |
| Escitalopram Oxalate | Escitalopram Oxalate | 62 | 21 |
| Allopurinol | Allopurinol | 60 | 16 |
| Duloxetine Hcl | Duloxetine Hcl | 57 | 11 |
| Carvedilol | Carvedilol | 53 | 17 |
| Pravastatin Sodium | Pravastatin Sodium | 53 | 16 |
| Atenolol | Atenolol | 52 | 14 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 52 | 15 |
| Breo Ellipta | Fluticasone/Vilanterol | 50 | suppressed |
| Ibuprofen | Ibuprofen | 49 | 15 |
| Celecoxib | Celecoxib | 48 | 14 |
| Morphine Sulfate Er | Morphine Sulfate | 48 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 47 | 11 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 46 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 45 | 11 |
| Alendronate Sodium | Alendronate Sodium | 44 | 14 |
| Clopidogrel | Clopidogrel Bisulfate | 43 | 12 |
| Mounjaro | Tirzepatide | 43 | suppressed |
| Clonazepam | Clonazepam | 40 | suppressed |
| Pregabalin | Pregabalin | 40 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 39 | 14 |
| Jardiance | Empagliflozin | 37 | suppressed |
| Meloxicam | Meloxicam | 37 | suppressed |
| Prednisone | Prednisone | 37 | 17 |
| Naproxen | Naproxen | 36 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 35 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 35 | 16 |
| Spironolactone | Spironolactone | 35 | 11 |
| Citalopram Hbr | Citalopram Hydrobromide | 34 | 12 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 34 | 12 |
| Divalproex Sodium | Divalproex Sodium | 33 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 32 | suppressed |
| Topiramate | Topiramate | 32 | suppressed |
| Levetiracetam | Levetiracetam | 31 | suppressed |
| Lovastatin | Lovastatin | 30 | suppressed |
| Digoxin | Digoxin | 29 | suppressed |
| Finasteride | Finasteride | 28 | suppressed |
| Fluconazole | Fluconazole | 28 | 11 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 27 | 11 |
| Methenamine Hippurate | Methenamine Hippurate | 27 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 27 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 27 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 27 | 16 |
| Valsartan | Valsartan | 27 | suppressed |
| Aripiprazole | Aripiprazole | 26 | suppressed |
| Azithromycin | Azithromycin | 26 | 24 |
| Diclofenac Sodium | Diclofenac Sodium | 26 | 15 |
| Donepezil Hcl | Donepezil Hcl | 26 | suppressed |
| Xarelto | Rivaroxaban | 26 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 25 | 21 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 25 | 20 |
| Paxlovid | Nirmatrelvir/Ritonavir | 25 | 25 |
| Sumatriptan Succinate | Sumatriptan Succinate | 25 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 24 | suppressed |
| Lansoprazole | Lansoprazole | 24 | suppressed |
| Trulicity | Dulaglutide | 24 | suppressed |
| Amoxicillin | Amoxicillin | 23 | 15 |
| Memantine Hcl Er | Memantine Hcl | 23 | suppressed |
| Carisoprodol | Carisoprodol | 22 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 22 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 22 | suppressed |
| Myrbetriq | Mirabegron | 21 | suppressed |
| Nystatin | Nystatin | 21 | suppressed |
| Synthroid | Levothyroxine Sodium | 21 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 20 | suppressed |
| Glipizide | Glipizide | 20 | suppressed |
| Torsemide | Torsemide | 20 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 20 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 19 | suppressed |
| Ezetimibe | Ezetimibe | 19 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 19 | suppressed |
| Methylprednisolone | Methylprednisolone | 19 | 17 |
| Nifedipine Er | Nifedipine | 19 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 19 | suppressed |
| Ondansetron Odt | Ondansetron | 19 | suppressed |
| Sucralfate | Sucralfate | 19 | suppressed |
| Baclofen | Baclofen | 18 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 18 | suppressed |
| Diazepam | Diazepam | 18 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 18 | suppressed |
| Lamotrigine | Lamotrigine | 18 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 17 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 17 | suppressed |
| Verapamil Er | Verapamil Hcl | 17 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Eszopiclone | Eszopiclone | 16 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 16 | suppressed |
| Fentanyl | Fentanyl | 16 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 16 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 16 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 16 | suppressed |
| Febuxostat | Febuxostat | 15 | suppressed |
| Lidocaine | Lidocaine | 15 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 15 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 14 | suppressed |
| Calcitriol | Calcitriol | 14 | suppressed |
| Chlorthalidone | Chlorthalidone | 14 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 14 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 14 | suppressed |
| Nitroglycerin | Nitroglycerin | 14 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 14 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 14 | suppressed |
| Sulfasalazine | Sulfasalazine | 14 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 13 | suppressed |
| Estradiol | Estradiol | 13 | suppressed |
| Methazolamide | Methazolamide | 13 | suppressed |
| Protonix | Pantoprazole Sodium | 13 | suppressed |
| Trospium Chloride | Trospium Chloride | 13 | suppressed |
| Armodafinil | Armodafinil | 12 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 12 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 12 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 12 | suppressed |
| Entresto | Sacubitril/Valsartan | 12 | suppressed |
| Januvia | Sitagliptin Phosphate | 12 | suppressed |
| Lactulose | Lactulose | 12 | suppressed |
| Linzess | Linaclotide | 12 | suppressed |
| Novolog Flexpen | Insulin Aspart | 12 | suppressed |
| Pradaxa | Dabigatran Etexilate Mesylate | 12 | suppressed |
| Ramelteon | Ramelteon | 12 | suppressed |
| Testosterone | Testosterone | 12 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 12 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 11 | suppressed |
| Cephalexin | Cephalexin | 11 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 11 | 11 |
| Methocarbamol | Methocarbamol | 11 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 11 | suppressed |
| Tadalafil | Tadalafil | 11 | suppressed |
| Zafirlukast | Zafirlukast | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $32.08 · 2 records | Lilly USA, LLC | ELIQUIS, MOUNJARO, ZEPBOUND | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with E.R. Squibb & Sons, L.L.C.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error